VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. has a strategic collaboration agreement with Chemveda Life Sciences to test and screen AI-derived drug compounds. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.…
BC-Most Active Stocks
VivoSim Labs (NASDAQ: VIVS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 0.2608 USD on 20 November 2026, down 88.1% over 52 weeks. Its 52-week range is 0.1180 USD to 3.400 USD: the price is 92.3% below the high and 121.0% above the low.
Its market capitalisation is 5.29M USD.
VivoSim Labs reports revenue down 51.4% year over year.
It holds more cash than debt, a net cash position of 1.35M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.